Equities

Nexgel Inc

NXGL:NAQ

Nexgel Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.26
  • Today's Change0.06 / 2.73%
  • Shares traded8.32k
  • 1 Year change+41.25%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 16:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Company’s converting and packaging business, which is based in Granbury, Texas. All of its gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty.

  • Revenue in USD (TTM)4.09m
  • Net income in USD-3.16m
  • Incorporated2009
  • Employees19.00
  • Location
    Nexgel Inc2150 Cabot Boulevard West, Suite BLANGHORNE 19047United StatesUSA
  • Phone+1 (215) 702-8550
  • Fax+1 (302) 636-5454
  • Websitehttps://nexgel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
America Great Health219.13k-859.20k12.67m7.00------57.81-0.00004-0.000040.00001-0.00020.67460.072118.1631,304.29-265.62-543.96----95.92-247.36-393.74-1,193.550.035-1.37----95.23--84.35------
NanoViricides Inc0.00-9.36m13.31m7.00--1.15-----0.8004-0.80040.000.98280.00----0.00-55.47-43.54-57.90-46.29------------0.00-------5.94---8.90--
Actavia Life Sciences Inc0.00-4.44m13.35m1.00---------0.0074-0.00740.00-0.00270.00----0.00-10,235.89-158.17---------------21.20---------547.04------
Check Cap Ltd0.00-17.62m13.45m85.00--0.4912-----3.01-3.010.004.680.00----0.00-44.86-58.80-48.21-66.41------------0.00-------11.08--16.04--
Akari Therapeutics PLC (ADR)0.00-10.01m13.47m9.00---------2.04-2.040.00-0.03460.00----0.00-110.06-149.95-1,281.64-435.18--------------------43.61------
Lotus Pharmaceuticals Inc70.79m1.72m13.47m233.000.09040.00143.490.19030.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Nexgel Inc4.09m-3.16m13.70m19.00--2.69--3.35-0.5566-0.55660.72120.8180.40273.819.57215,263.20-31.39-44.61-38.80-56.1915.165.02-77.95-180.981.46--0.1396--99.6613.0633.48------
Dominari Holdings Inc2.04m-22.88m13.75m26.00--0.2599--6.74-4.44-4.440.38998.920.0305--0.382978,423.08-34.20-26.82-35.10-27.45-----1,122.22-3,353.52----0.00----135.7512.72--63.99--
Microbot Medical Inc0.00-10.74m13.82m22.00--2.50-----1.08-1.080.000.38450.00----0.00-120.24-53.28-178.87-62.65------------0.00------18.44---31.76--
GlucoTrack Inc0.00-7.10m14.30m6.00--3.49-----0.3394-0.33940.000.1530.00----0.00-193.30-94.01-294.60-142.35-------10,447.96----0.0578-------60.02------
Kiora Pharmaceuticals Inc0.00-13.04m14.31m12.00--0.6874-----2.98-2.980.000.79290.00----0.00-77.27-70.52-91.06-81.86-------2,040.61----0.00------3.97------
Edesa Biotech Inc0.00-7.72m14.32m16.00--2.41-----2.60-2.600.001.850.00----0.00-79.13---95.05--------------0.00------52.28------
Pieris Pharmaceuticals Inc42.81m-24.54m14.44m46.00--0.5398--0.3374-22.94-22.9438.0321.640.6382--13.42930,652.20-36.58-28.41-57.30-39.69-----57.33-94.61----0.00--65.288.0326.25---36.82--
Vaxxinity Inc0.00-56.94m14.53m57.00--1.08-----0.4499-0.44990.000.10580.00----0.00-75.56---111.46--------------0.5308------24.31------
Data as of May 02 2024. Currency figures normalised to Nexgel Inc's reporting currency: US Dollar USD

Institutional shareholders

2.03%Per cent of shares held by top holders
HolderShares% Held
Simon Quick Advisors LLCas of 31 Mar 202435.72k0.58%
Geode Capital Management LLCas of 31 Dec 202330.27k0.49%
The Vanguard Group, Inc.as of 31 Dec 202325.53k0.41%
Renaissance Technologies LLCas of 31 Dec 202325.43k0.41%
Tower Research Capital LLCas of 31 Dec 20234.80k0.08%
NewEdge Advisors LLCas of 31 Dec 20233.50k0.06%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023600.000.01%
UBS Securities LLCas of 31 Dec 2023155.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Dec 202335.000.00%
Deutsche Bank Securities, Inc.as of 31 Dec 20230.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.